MeiraGTx to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
MeiraGTx Holdings plc (Nasdaq: MGTX) announced that CEO Alexandria Forbes, Ph.D., will present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, at 10:05 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MeiraGTx Holdings plc (Nasdaq: MGTX) announced that CEO Alexandria Forbes, Ph.D., will present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, at 10:05 a.m. ET. The presentation will be available via a live webcast on the company's Investors page. MeiraGTx is a clinical-stage gene therapy company with six programs in development, focusing on inherited retinal diseases, neurodegenerative diseases, and severe forms of xerostomia. The company aims to address significant medical needs through innovative gene therapy solutions.
Details
News Market Reaction – MGTX
The recorded move for MGTX in the trading session of this news was -2.97%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Evercore ISI 3rd Annual HealthCONx Conference at 10:05 a.m. ET on December 3, 2020.
A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.meiragtx.com. A replay of the webcast will be available for approximately 90 days following the presentation.
About MeiraGTx
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, neurodegenerative diseases and severe forms of xerostomia. Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.
For more information, please visit www.meiragtx.com.
Contacts
Investors:
MeiraGTx
investors@meiragtx.com
or
Media:
W2O pure
Christiana Pascale
(212) 257-6722
cpascale@purecommunications.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.